文献速递炎症性肠病

托法替布用于生物制剂经治的重症溃疡性结肠炎住院患者:回顾性病例对照研究

Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-05-25

该回顾性病例对照研究评估托法替布诱导治疗在生物制剂经治、需静脉糖皮质激素的重症溃疡性结肠炎(ASUC)住院患者中的疗效。

要点

  • 托法替布联合静脉激素可使生物制剂经治ASUC患者90天结肠切除风险降低(HR 0.28)。
  • 10mg每日三次剂量显示保护作用(HR 0.11),10mg每日两次未见显著保护。
  • 并发症与激素依赖率在托法替布组与对照组间相似。

核心结论

  • 托法替布联合静脉糖皮质激素可能是生物制剂经治ASUC住院患者的有效诱导策略。

研究设计与样本

  • 回顾性病例对照研究,评估托法替布诱导治疗在生物制剂经治、需静脉激素的ASUC住院患者中的疗效。
  • 采用调整疾病严重度的Cox回归估计90天结肠切除风险。

主要发现

  • 10mg每日两次亚组未见显著保护(HR 0.66,95%CI 0.21-2.09,P=0.5)。
  • 托法替布组与对照组并发症发生率和激素依赖率相似。

临床怎么用

  • 对生物制剂经治的ASUC住院患者,可考虑托法替布联合静脉激素作为诱导治疗以降低结肠切除风险。
  • 剂量选择上,10mg每日三次可能优于10mg每日两次,但需结合个体情况。

局限性

  • 回顾性设计存在选择偏倚和信息偏倚可能。
  • 需前瞻性试验确定托法替布用于ASUC的安全性、最佳剂量、频率和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase inhibitor with proven efficacy in ulcerative colitis. Tofacitinib may provide additional means for preventing colectomy in patients with ASUC. METHODS: A retrospective case-control study was performed evaluating the efficacy of tofacitinib induction in biologic-experienced patients admitted with ASUC requiring intravenous corticosteroids. Tofacitinib patients were matched 1:3 to controls according to gender and date of admission. Using Cox regression adjusted for disease severity, we estimated the 90-day risk of colectomy. Rates of complications and steroid dependence were examined as secondary outcomes. RESULTS: Forty patients who received tofacitinib were matched 1:3 to controls (n = 113). Tofacitinib was protective against colectomy at 90 days compared with matched controls (hazard ratio [HR], 0.28, 95% confidence interval [CI], 0.10-0.81; P = .018). When stratifying according to treatment dose, 10 mg three times daily (HR, 0.11; 95% CI, 0.02-0.56; P = .008) was protective, whereas 10 mg twice daily was not significantly protective (HR, 0.66; 95% CI, 0.21-2.09; P = .5). Rate of complications and steroid dependence were similar between tofacitinib and controls. CONCLUSIONS: Tofacitinib with concomitant intravenous corticosteroids may be an effective induction strategy in biologic-experienced patients hospitalized with ASUC. Prospective trials are needed to identify the safety, optimal dose, frequency, and duration of tofacitinib for ASUC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol. 2021. PMID: 34048936. doi:10.1016/j.cgh.2021.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。